PR Newswire
FREMONT, Calif., Aug. 1, 2018
FREMONT, Calif., Aug. 1, 2018 /PRNewswire/ -- Ardelyx,
Inc. (NASDAQ: ARDX) today announced that it plans to report its second quarter 2018 financial results after market close on
Tuesday, August 7, 2018. Management will host a conference call and webcast that afternoon at
4:30 p.m. ET to discuss the results and other business updates.
To participate in the conference call, please dial (855) 296-9612 (toll-free) or (920) 663-6277 (toll) and reference call ID
number 1592643. A webcast of the call can be accessed by visiting the Investor section of the Ardelyx website at ir.ardelyx.com.
A replay of the webcast will be available on the Ardelyx website for 60 days following the call.
About Ardelyx, Inc.
Ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class
medicines. Ardelyx's renal pipeline includes the Phase 3 development of tenapanor for the treatment of
hyperphosphatemia in people with end-stage renal disease who are on dialysis and RDX013, a potassium secretagogue program for the
potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. In
addition, Ardelyx has completed Phase 3 development of tenapanor for the treatment of irritable bowel syndrome with
constipation and anticipates submitting a New Drug Application to the U.S. Food and Drug Administration for this
indication in the second half of 2018. To efficiently bring its treatments to market, Ardelyx is pursuing strategic
collaborations in the U.S. and outside the U.S., with established agreements with Kyowa Hakko Kirin in Japan,
Fosun Pharma in China and Knight Therapeutics in Canada. For more information, please
visit http://www.ardelyx.com/ and connect with us
on Twitter @Ardelyx.
View original content with multimedia:http://www.prnewswire.com/news-releases/ardelyx-announces-date-of-second-quarter-2018-financial-results-and-conference-call-300689712.html
SOURCE Ardelyx
